Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000594799 | SCV000707497 | uncertain significance | not provided | 2017-04-25 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV002265818 | SCV002548722 | uncertain significance | Homocystinuria due to methylene tetrahydrofolate reductase deficiency | 2021-08-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002265818 | SCV003267645 | pathogenic | Homocystinuria due to methylene tetrahydrofolate reductase deficiency | 2024-01-21 | criteria provided, single submitter | clinical testing | This sequence change affects the initiator methionine of the MTHFR mRNA. The next in-frame methionine is located at codon 49. This variant is present in population databases (rs373076763, gnomAD 0.05%). This variant has not been reported in the literature in individuals affected with MTHFR-related conditions. ClinVar contains an entry for this variant (Variation ID: 501216). This variant disrupts a region of the MTHFR protein in which other variant(s) (p.Arg46Gln) have been determined to be pathogenic (PMID: 25736335, 28241805). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |